Genotype-guided choice of dual antiplatelet therapy just missed significance in reducing ischaemic events in patients with acute coronary syndrome and stable coronary artery disease who underwent percutaneous coronary intervention (PCI), according to the results of the two-arm, parallel, open-label, international, multicentre, randomized superiority TAILOR PCI trial presented at the American College of Cardiology 2020/World Congress of Cardiology (ACC.20/WCC) virtual meeting.
Catheter-based renal denervation (RDN), used without antihypertensive medications, significantly lowers blood pressure (BP) in patients with uncontrolled hypertension without major adverse events (AEs), according to results of the SPYRAL HTN-OFF MED Pivotal trial presented at the American College of Cardiology and World Congress of Cardiology virtual meeting (ACC.20/WCC).
Higher dietary protein intake was associated with a lower risk of developing atrial fibrillation (AF) in postmenopausal women compared with lower protein intake, according to a secondary analysis presented at the ACC.20/WCC Virtual Meeting.
In patients on long-term oral anticoagulant (OAC) therapy who are undergoing transcatheter aortic valve implantation (TAVI), post-procedure use of clopidogrel can be omitted to reduce bleeding without compromising antithrombotic efficacy, according to results from cohort B of the POPular TAVI trial presented at the American College of Cardiology and World Congress of Cardiology virtual meeting (ACC.20/WCC).
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.